TITLE

The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes

AUTHOR(S)
Hollander, Priscilla
PUB. DATE
January 2013
SOURCE
U.S. Endocrinology;Winter2013, Vol. 9 Issue 2, p101
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The prevalence of diabetes continues to rise, following the rising rates of obesity. Obesity is not only associated with an increased risk for developing type 2 diabetes but also an elevated probability of developing long-term complications associated with the disease. Weight gain is also an important concern as a potential side effect of therapies that improve glycemic control in diabetes, including insulin therapy. As a result, patients with type 2 diabetes are at risk for a vicious circle of increasing weight and increasing insulin resistance, thus requiring further intensification of glycemic treatment. It is therefore important to address the problem of obesity in patients with type 2 diabetes. In 2012, the US Food and Drug Administration (FDA) approved two new anti-obesity medications: lorcaserin and phentermine/topiramate extended-release. Both agents have demonstrated clinically meaningful weight reduction as well as significant improvements in glycemic control in obese patients with diabetes. Liraglutide has also shown weight loss and improvements in glycemic control in patients with diabetes. Anti-obesity drugs, in conjunction with lifestyle changes, may play a valuable role in the management of diabetes.
ACCESSION #
94783564

 

Related Articles

  • Screening of Crude Plant Extracts with Anti-Obesity Activity. Changhyun Roh; Uhee Jung // International Journal of Molecular Sciences;Feb2012, Vol. 13 Issue 2, p1710 

    Obesity is a global health problem. It is also known to be a risk factor for the development of metabolic disorders, type 2 diabetes, systemic hypertension, cardiovascular disease, dyslipidemia, and atherosclerosis. In this study, we screened crude extracts from 400 plants to test their...

  • Current models and strategies in the development of antiobesity drugs. Kinsey‐Jones, James S.; Murphy, Kevin G. // Annals of the New York Academy of Sciences;Dec2011, Vol. 1245 Issue 1, p3 

    Animal models have enabled investigation of the complex mechanisms underlying energy homeostasis and, therefore, the development of antiobesity drugs.

  • Insulin Resistance in the Offspring of Parents with Type 2 Diabetes. Wagenmakers, Anton J. M. // PLoS Medicine;Sep2005, Vol. 2 Issue 9, p839 

    Focuses on a study which examined insulin resistance (IR) in the offspring of parents with type 2 diabetes. Information on the offspring with IR used in the study; Effect of the infusion of insulin on the turnover rate of adenosine triphosphate (ATP); Significance of the ATP increase.

  • Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes. Davies, Melanie J.; Bergenstal, Richard; Bode, Bruce; Kushner, Robert F.; Lewin, Andrew; Skjøth, Trine Vang; Andreasen, Arne Haahr; Jensen, Christine Bjørn; DeFronzo, Ralph A. // JAMA: Journal of the American Medical Association;8/18/2015, Vol. 314 Issue 7, p687 

    IMPORTANCE Weight loss of 5% to 10% can improve type 2 diabetes and related comorbidities. Few safe, effective weight-management drugs are currently available. OBJECTIVE To investigate efficacy and safety of liraglutide vs placebo for weight management in adults with overweight or obesity and...

  • Pharmacologic interventions for weight-related health risks. BAYS, HAROLD E.; BILLES, SONJA K. // Clinical Advisor;Oct2014, Vol. 17 Issue 10, p51 

    No abstract available.

  • Medications for Weight Loss in Patients with Type 2 Diabetes Mellitus. Kachowski, Larisa; Over, Darrell R.; Kefeng Qiu // American Family Physician;3/15/2012, Vol. 85 Issue 6, p633 

    The article discusses weight-loss medications that are effective and safe for use in patient with type 2 diabetes mellitus. Both fluoxetine (Prozac) and orlistat (Xenical) can produce modest short-term weight loss. The usefulness of topiramate (Topamax) was limited by potential psychiatric and...

  • Part 1: Rationale for a Wellness Approach to Obesity. Ernsberger, Paul; Koletsky, Richard J. // Healthy Weight Journal;Jan/Feb2000, Vol. 14 Issue 1, p7 

    Part I. Proposes the wellness approach to treating disease in obesity. Link between obesity and type 2 diabetes; Effectiveness of weight loss as medical treatment for diabetes; Prevalence of hypertension and hypercholesterolemia in obese women and men.

  • Scientists discover a gene involved in diabetes and obesity. Josefson, Deborah // BMJ: British Medical Journal (International Edition);03/13/99, Vol. 318 Issue 7185, p689 

    Reports on the gene discovered by Canadian scientists that is implicated in obesity and type 2 diabetes. Significance of the discovery; Experimental procedure involving mice; Mechanism of increased insulin sensitivity.

  • Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Greco, Aldo V.; Mingrone, Gertrude; Giancaterini, Annalisa; Manco, Melania; Morroni, Manrico; Cinti, Saverio; Granzotto, Marnie; Vettor, Roberto; Camastra, Stefania; Ferrannini, Ele // Diabetes;Jan2002, Vol. 51 Issue 1, p144 

    Obesity is a frequent cause of insulin resistance and poses a major risk for diabetes. Abnormal fat deposition within skeletal muscle has been identified as a mechanism of obesity-associated insulin resistance. We tested the hypothesis that dietary lipid deprivation may selectively deplete...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics